Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

Presentation: Metabolomics for discovering the functions of genes with embryonic-lethal mutations (Agilent)

7 Oct 2014
General interest

Presentation held by Steven S. Gross, Department of Pharmacology Weill Cornell Medical College (NY, NY).

sgross

 

Click here to view presentation.

Related Links

  • Agilent Technologies

 

Top content

  • AI-powered liquid biopsy could uncover early signs of liver disease
  • US FDA takes further steps to streamline biosimilar development
  • What to look out for at Analytica 2026

Related tags

metabolomics
Previous article Next article

Related articles

31 OCT 2016 JOURNAL ARTICLES
A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites
22 MAY 2014 GENERAL INTEREST
New combination of biomarkers identified for the detection of Alzheimer’s disease
22 MAR 2019 INTERVIEWS
An author’s perspective: George Jaskiw on quantification of phenolic acid metabolites in humans by LC–MS
28 JUL 2015 CHROMATOGRAPHY
High-throughput bioanalytical workflow for metabolic profiling of biological samples (Agilent)
11 OCT 2012 DATA PROCESSING AND INTERPRETATION
Maximizing the value of metabolomic data
5 NOV 2013 COLLABORATIONS AND MERGERS
Strategic alliance announced for neurometabolomics research
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone